Copyright © 2003 by the European Society of Cardiology.
Regular Articles
Abciximab-facilitated percutaneous coronary intervention and long-term survival—a prospective single-center registry
a Department of Cardiology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F-25, Cleveland,OH 44195, USA
b Department of Biostatistics, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F-25, Cleveland, OH 44195, USA
* Corresponding author. Tel.: +1-216-444-0732; fax: +1-216-444-8050
E-mail address: breners{at}ccf.org
Received 25 October 2002; accepted 29 October 2002
Aims To identify predictors of use of abciximab and evaluate the long-term survival after percutaneous coronary intervention with or without abciximab in a broad spectrum of patients.
Methods We prospectively evaluated, in a dedicated registry, the 4-year survival of patients undergoing percutaneous revascularization and the treatment with or without abciximab, using the Social Security Death Index.
Results Among 10,471 patients treated between 2/1/1995 and 12/31/2001, 5655 received abciximab and 4816 did not. Propensity score analysis (c-statistic 0.83) identified the following variables to be independently associated with abciximab use: later date of procedure, stent use, acute or recent infarction, increasing lesion complexity, vein graft intervention, hyperlipidemia, normal renal function, male gender and decreasing age. Procedural success was higher in the abciximab group, 93 vs. 89%, 
. Unadjusted Kaplan–Meyer survival analysis demonstrated a strong trend for improved survival in the abciximab group at 4 years, 86.3 vs. 84.7%, 
. In the 7533 patients with acute coronary syndromes (ACS), the respective values were 86.0 vs. 83.6%, 
. Multivariate Cox proportional hazard analysis identified increasing age, significant left ventricular dysfunction or congestive heart failure, chronic renal insufficiency and diabetes mellitus as main predictors of mortality. Abciximab was independently associated with improved survival only in patients with ACS (adjusted HR 0.87, 95% confidence interval, 0.81–1.00, 
). Abciximab use was associated with a higher rate of access site hematoma (2.8 vs. 1.5%) and blood product transfusion (6.8% vs. 4.8%), for both.
Conclusion Abciximab use improves procedural success and is associated with lower 4-year mortality in patients with ACS, for whom it should be strongly considered. A lesser effect is seen in patients without high-risk characteristics.
List of Abbreviations: CABG=Coronary artery bypass grafting • CCF=Cleveland Clinic Foundation • CI=Confidence interval • EPIC=Evaluation of c7E3 for the prevention of ischemic complications • EPILOG=Evaluation of PTCA to improve long-term outcome by c7E3 glycoprotein receptor blockade • EPISTENT=Evaluation of platelet IIb/IIIa inhibitor for stenting • GP IIb/IIIa=Platelet glycoprotein IIb/IIIa receptor • HR=Hazard ratio • MI=Myocardial infarction • PCI=Percutaneous coronary intervention • RCT=Randomized clinical trial • TIMI flow grade=Thrombolysis in myocardial infarction flow grade
Key Words: Abciximab • Percutaneous coronary intervention • Survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Ndrepepa, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, M. Seyfarth, J. Pache, J. Dirschinger, et al. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial Eur. Heart J., February 2, 2008; 29(4): 455 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot, D. Antoniucci, A. Kastrati, F. J. Neumann, M. Borentain, A. Migliorini, C. Boutron, J.-P. Collet, and E. Vicaut Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up Eur. Heart J., February 2, 2007; 28(4): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Heer, U Zeymer, C Juenger, A K Gitt, H Wienbergen, R Zahn, M Gottwik, J Senges, and for the Acute Coronary Syndromes (ACOS) Registry I Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice Heart, October 1, 2006; 92(10): 1484 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The ADMIRAL Investigators Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study Eur. Heart J., December 1, 2005; 26(23): 2520 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Elsasser and C. W. Hamm Percutaneous coronary intervention guidelines: new aspects for the interventional treatment of acute coronary syndromes Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K5 - K9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sciagra, G. Parodi, A. Pupi, A. Migliorini, R. Valenti, G. Moschi, G. M. Santoro, G. Memisha, and D. Antoniucci Gated SPECT Evaluation of Outcome After Abciximab-Supported Primary Infarct Artery Stenting for Acute Myocardial Infarction: The Scintigraphic Data of the Abciximab and Carbostent Evaluation (ACE) Randomized Trial J. Nucl. Med., May 1, 2005; 46(5): 722 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams? Eur. Heart J., September 2, 2004; 25(18): 1562 - 1564. [Full Text] [PDF]
|
|